VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2020 | Cytoreductive nephrectomy for RCC

Ziad Bakouny • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab Sunitinib
CARMENA CYTOSHRINK NORDIC-SUN PROBE Immuno-Oncology

Ziad Bakouny, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his analysis of cytoreductive nephrectomy for metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors or targeted therapy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Ziad Bakouny

4:49
Potential prognostic markers in sarcomatoid and rhabdoid RCC
Ziad Bakouny • 13 Feb 2020
2:41
Translational approaches in immunotherapy
Ziad Bakouny • 15 Feb 2020
3:03
Next-gen immuno-oncology therapies in RCC
Ziad Bakouny • 14 Feb 2020

Related Videos

4:12
CABOSUN trial of cabozantinib - could it change how we treat frontline RCC?
Toni Choueiri
4:43
Erdafitinib for FGFR-mutated urothelial carcinoma
Arlene Siefker-Radtke
4:00
Upcoming therapies in the metastatic urothelial carcinoma space
Thomas Powles
1:02
Current status of VEGF inhibitor/immunotherapy combinations in RCC
Bradley McGregor
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals